Risk for Cardiovascular Adverse Events Associated With Sphingosine-1-Phosphate Receptor Modulators in Patients With Multiple Sclerosis: Insights From a Pooled Analysis of 15 Randomised Controlled Trials

BACKGROUND: All agents engaging sphongosine-1-phospate receptors (S1PRs) will have some cardiovascular effect. This study aimed to elucidate the risk of cardiovascular adverse events (AEs) in patients with multiple sclerosis (MS) treated with S1PR modulators (S1PRMs). METHODS: We systematically sear...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Zhao, Lv, Yang, Gu, Zhi-Chun, Ma, Chun-Lai, Zhong, Ming-Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688957/
https://www.ncbi.nlm.nih.gov/pubmed/34950154
http://dx.doi.org/10.3389/fimmu.2021.795574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8688957/
https://www.ncbi.nlm.nih.gov/pubmed/34950154
http://dx.doi.org/10.3389/fimmu.2021.795574

Ejemplares similares